INHIBITORY EFFECT OF REINIOSIDE C ON VASCULAR SMOOTH MUSCLE CELLS PROLIFERATION INDUCED BY ANGIOTENSIN II VIA INHIBITING NADPH OXIDASE-ROS-ERK1/2-NF-KB-AP-1 PATHWAY

doi:10.1136/heartjnl-2012-302920b.26

1Dan Hong, 1Rui-Zheng Shi, 1Yong-Ping Bai, 2Chang-Ping Hu, 3Gui-Shan Tan, 3Yuan-Jian Li, 3Tian-Lun Yang, 3Kang-Ping Xu, 3Guo-Gang Zhang. 1Department of Cardiovascular Medicine, Xiangya Hospital, Central South University; 2Department of Pharmacology, School of Pharmaceutical Sciences, Central South University; 3Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Central South University.
**Objectives** Proliferation of vascular smooth muscle cells (VSMCs) induced by angiotensin II (Ang II) plays a vital role in the pathogenesis of hypertension. In the present study, the effect of reinioside C, a main active ingredient of Polygalafallax Hemsl, on proliferation of VSMCs induced by Ang II was investigated.

**Methods** Cell proliferation was measured by two methods; the DNA synthesis and cell cycle were analysed by BrdU marking and flow cytometry. Intracellular ROS level were determined by measuring the oxidative conversion of cell permeable H2DCF to DCF in fluorospectrophotometer. NADPH oxidase subunits (p22phox, gp91phox), AP-1 subunits (c-fos, c-jun) and c-myc were evaluated by real time PCR. ERK1/2 and IκB-α were measured by western-blot. The electrophoretic mobility shift assay for determining the NF-kB DNA-binding activity.

**Results** The results showed that reinioside C attenuated Ang II-induced NADPH oxidase mRNA expression, generation of ROS, ERK1/2 phosphorylation and activation of NF-κB as well as mRNA expression of AP-1 and c-myc in VSMCs in a concentration-dependent manner. These effects of Ang II were also inhibited by diphenyleneiodonium (the NADPH oxidase inhibitor), PD98059 (the ERK1/2 inhibitor) and pyrrolidinedithiocarbamate (the NF-κB inhibitor).

**Conclusions** These results suggest reinioside C attenuates AngII-induced proliferation of VSMC via inhibiting NADPH oxidase- ROS- ERK1/2- NF-kB -AP-1 pathway.